Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg
Steffen
S
Harvard Medical School and at the CBR Institute for Biomedical Research, Boston, USA.
von Andrian
Ulrich H
UH
D000818:Animals; D001324:Autoantigens; D002465:Cell Movement / Q000187:drug effects; D002490:Central Nervous System / Q000276:immunology; D015536:Down-Regulation; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000276:immunology; D008246:Lysophospholipids / Q000819:agonists / Q000378:metabolism; D009103:Multiple Sclerosis / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013110:Sphingosine / Q000009:adverse effects / Q000819:agonists / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects* / Q000502:physiology
D001324:Autoantigens; D007166:Immunosuppressive Agents; D008246:Lysophospholipids; D011409:Propylene Glycols; C060506:sphingosine 1-phosphate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine